mdk

MDK-6983 (MDK-6983) is an inhibitor of autophagy and disrupts the dynamics of actin cytoskeleton in human melanoma cells.

MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.

MDK6204 is a selective inhibitor of CLK1 and CLK2.

MDK-4823, also known as LMPTP inhibitor1, is a potent low-molecular-weight tyrosine phosphatase (LMPTP) inhibitor. LMPTP is highly expressed in insulin-target tissues. LMPTP promotes diabetes and insulin resistance in obesity.

MDK08445 is an important intermediate or precursor for the synthesis of Cefiderocol, a potent siderophore cephalosporin antibiotic.

MDK-2959 is a potent inhibitor of protein tyrosine phosphatase sigma (PTPsigma).

MDK-3298 is a reversible covalent inhibitor of Mcl-1, a target of protein-protein interaction (PPI).

MDK-3345 is a reversible covalent inhibitor for Mcl-1.

MDK49781 is a useful chemical intermediate for drug synthesis.

MDK71803 is an important intermediate or precursor for the synthesis of Cefiderocol, a potent siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain.

MDK3673, also known as Olfr895-Agonist-10, is a novel specific agonist of odorant receptor 895 (Olfr895).

MDK6465, also known as PCSK9-IN-8b, is a novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). MDK6465 has CAS#1900686-46-5. the last 4 digits are used in its name.

MDK80908, also known as PPARalpha/gamma agonist N15, is a dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro. MDK80908 has CAS#1821380-90-8.

MDK03855, also known as A2AR antagonist 19, is an adenosine A2A receptor (A2AR) antagonist. MDK03855 has CAS#1454903-85-5. The last five digit of CAS# was used for name.

iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.

BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association

MDK83190 (Apoptosis Activator 2) is a potent apoptosis activator, induceing caspase-3 activation, PARP cleavage, and DNA fragmentation .

MDK-4025 is an inhibitor of the high voltage-activated (HVA) Ca2+ current in pyramidal neurons.

GX-585 is a sulfonamide analog that is a Nav 1.7 channel inhibitor with analgesic activity for the study of neuropathic pain and inflammation.

BEBT-908 (PI3Kα inhibitor 1) is a selective PI3Kα inhibitor with an IC50 of less than 0.1 μM and also inhibits HDAC with an IC50 ranging from 0.1 μM to 1 μM.

PIK-inhibitors (MDK34597) is a pan PI3K inhibitors, an analog of PI-103.

T.cruzi-IN-1 (MDK1088) is a Trypanosoma cruzi inhibitor.

Pim1/AKK1-IN-1 (LKB1/AAK1 dual inhibitor) is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively, and also inhibits MPSK1 and TNIK.

TR-14035 (MDK-1191) is a dual antagonist of α4β7/α4β1 integrins (IC50s: 7/87nM).